Notably, the appearance of AD biomarkers can occur over an extended period prior to initiation of cognitive impairment, with reports showing cerebrospinal fluid Aβ42 can precede the first signs of cognitive impairment by over 10 years, whereas abnormal levels of tau are detected shortly before the first signs of cognitive impairment [116, 117]. This evidence concerns the gene MAPT and Alzheimer disease.